文献速递膀胱癌与上尿路尿路上皮癌

尿路上皮膀胱癌的分子图谱:连接肿瘤生物学与临床决策

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
PubMed 文献 · Eur Urol Oncol · 2026-07-08

本文为靶向叙述性综述,基于2000年1月至2026年2月的PubMed结构化检索,综合非肌层浸润性、肌层浸润性和转移性尿路上皮膀胱癌的基因组、表观遗传和转录组改变及其临床意义。文章指出分子分型已识别可重复的分子亚型,但当前仅FGFR3改变指导治疗(erdafitinib获批),临床实施仍有限,需前瞻性生物标志物驱动试验。

要点

  • NMIBC常见FGFR3、PIK3CA突变、9号染色体缺失和染色质重塑基因改变。
  • MIBC基因组不稳定高,常见TP53、RB1和染色质修饰基因突变及RTK/RAS/PI3K通路改变。
  • 共识转录组分类识别管腔型、基底/鳞状型、间质丰富型和神经内分泌样亚型。

核心结论

  • 分子图谱加深了对膀胱癌生物学的理解,并识别了诊断、预后和治疗的潜在生物标志物,但临床实施仍有限。
  • 需要前瞻性生物标志物驱动试验来确定基因组和转录组改变在治疗决策中的作用。

研究设计与样本

  • 靶向叙述性综述,基于2000年1月至2026年2月PubMed结构化检索,关键词为基因组、表观遗传、转录组和尿路上皮膀胱癌。
  • 纳入英文原始研究、综述和荟萃分析,证据按NMIBC、MIBC和转移性疾病综合。

主要发现

  • NMIBC和MIBC均常见TERT启动子突变。
  • NMIBC以FGFR3和PIK3CA突变、9号染色体缺失及染色质重塑基因改变为特征。
  • MIBC显示高基因组不稳定,反复出现TP53、RB1和染色质修饰基因突变及RTK/RAS/PI3K通路改变。
  • 共识转录组分类识别管腔型、基底/鳞状型、间质丰富型和神经内分泌样亚型,各具不同生物学和临床行为。
  • 转移性疾病中NGS和全外显子分析与原发肿瘤高度一致,常见TP53、ARID1A、KMT2D、RB1和FGFR3改变及APOBEC突变特征。

关键数值与推荐

  • 仅FGFR3改变目前指导治疗:erdafitinib获FDA和EMA批准用于FGFR3改变的转移性尿路上皮膀胱癌。
  • 循环肿瘤DNA检测在分子残留病检测和辅助治疗分层中显示前景。

临床怎么用

  • 对转移性尿路上皮膀胱癌患者应检测FGFR3改变以指导erdafitinib治疗。
  • 分子分型(管腔型、基底/鳞状型等)可用于预后评估和未来临床试验分层。
  • 循环肿瘤DNA有望用于分子残留病检测和辅助治疗决策。

局限性

  • 分子图谱的临床实施仍有限,除FGFR3外缺乏指导治疗的生物标志物。
  • 需要前瞻性生物标志物驱动试验验证基因组和转录组改变的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bladder cancer ranks among the most common malignancies worldwide, with urothelial carcinoma as the predominant histological type. Its development from normal urothelium to non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) is driven by complex molecular events, including chromosomal aberrations, somatic mutations, and epigenetic dysregulation. Advances in next-generation sequencing (NGS) and transcriptomic profiling have transformed the understanding of urothelial tumor biology and opened new perspectives for precision oncology. OBJECTIVE: To provide an updated synthesis of molecular profiling in urothelial bladder cancer across disease stages and to discuss its diagnostic, prognostic, and therapeutic relevance. EVIDENCE ACQUISITION: We conducted a targeted narrative review based on a structured PubMed search of studies published between January 2000 and February 2026 using the keywords "genomic," "epigenetic," "transcriptomic," and "urothelial bladder cancer." Eligible publications included original research articles, reviews, and meta-analyses in English. Evidence was synthesized across NMIBC, MIBC, and metastatic disease, focusing on molecular alterations and their clinical relevance. EVIDENCE SYNTHESIS: Both NMIBC and MIBC present frequent TERT promoter mutations. NMIBC is further characterized by frequent FGFR3 and PIK3CA mutations, loss of chromosome 9, and widespread chromatin-remodeling gene alterations. MIBC displays high genomic instability, with recurrent mutations in TP53, RB1, and chromatin modifiers, as well as frequent alterations in the RTK/RAS/PI3K pathway. Consensus transcriptomic classifications identify reproducible molecular subtypes (luminal, basal/squamous, stroma rich, and neuroendocrine like), each with distinct biological and clinical behaviors. In metastatic disease, NGS and whole-exome analyses reveal strong concordance with localized tumors, with frequent TP53, ARID1A, KMT2D, RB1, and FGFR3 alterations and APOBEC mutational signatures. Transcriptomic profiling shows subtype heterogeneity and therapy-induced remodeling. Clinically, only FGFR3 alterations currently guide therapy, with erdafitinib approved by the US Food and Drug Administration and the European Medicines Agency for FGFR3-altered metastatic disease. Beyond tumor testing, circulating tumor DNA assays show promise for molecular residual disease detection and adjuvant treatment stratification. CONCLUSIONS: Molecular profiling has deepened the understanding of bladder cancer biology and identified potential biomarkers for diagnosis, prognosis, and treatment. However, clinical implementation remains limited, and prospective biomarker-driven trials are needed to establish the role of genomic and transcriptomic alterations in therapeutic decision-making.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Thibault C, Blons H, Allory Y, et al. Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. Eur Urol Oncol. 2026. PMID: 42420157. doi:10.1016/j.euo.2026.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。